SCHEMBL24304595

SCHEMBL24304595

CCCCCCCCCCCCCCCCCCOC[C@H](CO[Si](C)(C)C(C)(C)C)OCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 9/20 0.37
IDO1 P14902 2/20 0.35
PLA2G10 O15496 2/20 0.34
PLA2G1B P04054 2/20 0.34
PLA2G5 P39877 2/20 0.34
SIGMAR1 Q99720 1/20 0.33
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
LPAR1 Q92633 4/20 0.32
LPAR3 Q9UBY5 4/20 0.32
LPAR2 Q9HBW0 1/20 0.32
MEN1 O00255 1/20 0.32
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29413327 0.98 PLA2G2A (0.36) PLA2G2AIDO1PLA2G10PLA2G1BPLA2G5
SCHEMBL24304620 0.90 SMN1; SMN2 (0.36) PLA2G2APLA2G10PLA2G1BPLA2G5LPAR2
SCHEMBL24304365 0.85 PLA2G2A (0.37) PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1
SCHEMBL25973993 0.84 IDO1 (0.39) PLA2G2AIDO1SIGMAR1LPAR1LPAR3
SCHEMBL29413318 0.83 PLA2G2A (0.36) PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1
SCHEMBL10043029 0.83 PLA2G2A (0.43) PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1
SCHEMBL25967589 0.83 PLA2G2A (0.43) PLA2G2APLA2G10PLA2G1BPLA2G5LPAR1
SCHEMBL25967477 0.82 PLA2G2A (0.43) PLA2G2APLA2G10PLA2G1BPLA2G5
SCHEMBL24304580 0.81 PLA2G2A (0.47) PLA2G2APLA2G10PLA2G1BPLA2G5HPGD
SCHEMBL24304712 0.81 USP2 (0.42) IDO1SIGMAR1CNR1CNR2LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030904-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-07-09 US disclosed
US-12030904-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-07-09 US disclosed
US-20240025932-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2024-01-25 US disclosed
US-20240025932-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2024-01-25 US disclosed
US-11773122-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES. INC. (US) 2023-10-03 US disclosed
US-11773122-B2 Phospholipid compounds and uses thereof GILEAD SCIENCES. INC. (US) 2023-10-03 US disclosed
US-20230250117-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-08-10 US disclosed
US-20230250117-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2023-08-10 US disclosed
US-20220081455-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2022-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030904-B2 Phospholipid compounds and uses thereof PHOSPHO1, SGMS2, SGMS1 PLA2G2A 29/4885IDO1 3203/4885PLA2G10 31/4885
US-20230250117-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF PHOSPHO1, SGMS2, SGMS1 PLA2G2A 29/4885IDO1 3203/4885PLA2G10 31/4885
US-20220081455-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF PHOSPHO1, SGMS2, SGMS1 PLA2G2A 29/4885IDO1 3203/4885PLA2G10 31/4885
US-20240025932-A1 PHOSPHOLIPID COMPOUNDS AND USES THEREOF PHOSPHO1, SGMS2, SGMS1 PLA2G2A 29/4885IDO1 3203/4885PLA2G10 31/4885
US-11773122-B2 Phospholipid compounds and uses thereof PHOSPHO1, SGMS2, SGMS1 PLA2G2A 29/4885IDO1 3203/4885PLA2G10 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.